

**Supplementary material**

**Chokeberry juice containing polyphenols does not affect cholesterol or blood pressure but modifies the composition of plasma phospholipids fatty acids in individuals at cardiovascular risk**

Biljana Pokimica<sup>1</sup>, María-Teresa García-Conesa<sup>2,\*</sup>, Manja Zec<sup>1</sup>, Jasmina Debeljak-Martačić<sup>1</sup>, Slavica Ranković<sup>1</sup>, Nevena Vidović<sup>1</sup>, Gordana Petrović-Oggiano<sup>1</sup>, Aleksandra Konić-Ristić<sup>1</sup>, and Maria Glibetić<sup>1</sup>

**Table S1.** Baseline characteristics of the sample population as distributed into the placebo (PLB) and chokeberry (AMJ and AMJ<sub>d</sub>) intervention groups.

	PLB (n=29)	AMJ (n=27)	AMJ <sub>d</sub> (n=28)	p-value (between groups)
Age				
Mean ± SD	39.00 ± 6.56	42.28 ± 7.45	40.75 ± 7.13	
95% CI	36.61 – 41.39	39.45 – 45.10	38.11 – 43.39	0.25
CV (%)	16.83	17.72	17.49	
Sex (% women)	48.3	62.9	75	-
Body mass index (Kg/m <sup>2</sup> )				
Mean ± SD	28.02 ± 5.49	28.46 ± 4.09	28.40 ± 5.20	
95% CI	26.02 – 30.02	26.92 – 30.00	26.47 – 30.32	0.82
CV (%)	19.59	14.35	18.31	
Systolic blood pressure (mm Hg)				
Mean ± SD	123.78 ± 20.37	125.89 ± 11.67	120.23 ± 9.78	
95% CI	116.36 – 131.19	121.49 – 130.29	116.61 – 123.85	0.26
CV (%)	16.45	9.27	8.13	
Diastolic blood pressure (mm Hg)				
Mean ± SD	76.29 ± 13.60	79.09 ± 9.90	74.89 ± 9.68	
95% CI	71.34 – 81.24	75.36 – 82.83	71.31 – 78.48	0.36
CV (%)	17.83	12.52	12.92	
Total cholesterol (mmol/L)				
Mean ± SD	5.41 ± 1.05	5.32 ± 1.09	5.11 ± 0.87	
95% CI	5.03 – 5.79	4.91 – 5.72	4.79 – 5.43	0.44
CV (%)	19.48	20.43	17.04	
LDL cholesterol (mmol/L)				
Mean ± SD	3.77 ± 0.99	3.60 ± 1.08	3.40 ± 0.81	
95% CI	3.41 – 4.13	3.19 – 4.01	3.10 – 3.70	0.26
CV (%)	26.22	30.11	23.66	
Triglycerides (mmol/L)				
Mean ± SD	1.44 ± 0.83	1.27 ± 0.73	1.07 ± 0.57	
95% CI	1.14 – 1.75	0.99 – 1.55	0.85 – 1.28	0.05
CV (%)	57.38	57.61	53.52	
Fasting serum glucose (mmol/L)				
Mean ± SD	5.28 ± 0.80	4.94 ± 0.50	4.87 ± 0.52	
95% CI	4.99 – 5.57	4.75 – 5.13	4.68 – 5.06	0.08
CV (%)	15.18	10.17	10.58	
oxLDL (ng/mL)				
Mean ± SD	114.75 ± 32.66	131.00 ± 24.01	126.30 ± 21.74	
95% CI	96.27 – 133.23	117.41 – 144.59	112.83 – 139.77	0.46
CV (%)	28.46	18.33	17.21	
oxLDL/total cholesterol (ng/mg)				
Mean ± SD	54.13 ± 16.62	62.77 ± 13.12	66.34 ± 14.01	
95% CI	44.73 – 63.54	55.34 – 70.19	57.66 – 75.02	0.22
CV (%)	30.70	20.90	21.11	
oxLDL/LDL cholesterol (ng/mg)				
Mean ± SD	78.51 ± 26.61	91.54 ± 27.11	97.74 ± 27.04	
95% CI	63.45 – 93.56	76.20 – 106.88	80.98 – 114.50	0.23
CV (%)	33.90	29.61	27.67	

Values are mean ± standard deviation (SD), 95% confidence interval (CI) and coefficient of variation (CV). Between groups differences were estimated by the non-parametric test of Kruskal-Wallis. All the p-values are indicated. LDL: low-density lipoprotein; oxLDL: oxidized low-density lipoprotein.

**Table S2.** Baseline waist circumference and HDL-cholesterol values in women and men as distributed in the three intervention subgroups: placebo (PLB) and chokeberry juices (AMJ and AMJ<sub>d</sub>).

Women	PLB (n=14)	AMJ (n=17)	AMJ <sub>d</sub> (n=21)	p-value (between groups)
Waist circumference (cm)				
Mean ± SD	89.57 ± 16.63	90.18 ± 13.55	86.38 ± 10.21	
95% CI	80.86–98.28	83.73–96.62	82.01–90.75	0.86
CV (%)	18.56	15.03	11.82	
HDL cholesterol (mmol/L)				
Mean ± SD	1.86 ± 0.41	1.71 ± 0.54	1.78 ± 0.42	
95% CI	1.64–2.07	1.45–1.96	1.60–1.96	0.52
CV (%)	22.10	31.66	23.87	
Total-cholesterol/HDL cholesterol				
Mean ± SD	3.14 ± 0.71	3.19 ± 0.90	3.02 ± 0.78	
95% CI	2.77–3.51	2.76–3.62	2.68–3.35	0.77
CV (%)	22.65	28.21	25.86	
LDL-cholesterol/HDL-cholesterol				
Mean ± SD	2.13 ± 0.64	2.11 ± 0.78	2.01 ± 0.70	
95% CI	1.80–2.47	1.74–2.47	1.71–2.31	0.83
CV (%)	30.08	36.89	34.91	
Men	PLB (n=15)	AMJ (n=10)	AMJ <sub>d</sub> (n=7)	
Waist circumference (cm)				
Mean ± SD	100.00 ± 8.47	100.80 ± 12.44	105.43 ± 7.21	
95% CI	95.71–104.29	93.45–108.15	100.09–110.77	0.36
CV (%)	8.47	12.34	6.84	
HDL cholesterol (mmol/L)				
Mean ± SD	1.26 ± 0.23	1.45 ± 0.43	1.45 ± 0.34	
95% CI	1.14–1.37	1.19–1.71	1.20–1.71	0.21
CV (%)	18.17	29.43	23.70	
Total-cholesterol/HDL cholesterol				
Mean ± SD	4.29 ± 1.25	4.25 ± 1.68	3.60 ± 1.00	
95% CI	3.65–4.92	3.21–5.29	2.86–4.34	0.40
CV (%)	29.23	39.44	27.73	
LDL-cholesterol/HDL-cholesterol				
Mean ± SD	3.11 ± 1.16	3.05 ± 1.45	2.51 ± 0.88	
95% CI	2.52–3.70	2.15–3.95	1.85–3.16	0.31
CV (%)	37.41	47.49	35.21	

Values are mean ± standard deviation (SD), 95% confidence interval (CI) and coefficient of variation (CV). Between groups differences were estimated by the non-parametric test of Kruskal-Wallis. All the p-values are indicated. HDL: high-density lipoprotein; LDL: low-density lipoprotein.

**Table S3.** Baseline plasma phospholipid fatty acid composition and desaturase activity for the three intervention groups: placebo (PLB) and chokeberry juices (AMJ and AMJ<sub>d</sub>).

	PLB (n=26)	AMJ (n=27)	AMJ <sub>d</sub> (n=27)	p-value (between groups)
<b>Fatty acid composition</b>				
Palmitic acid, 16:0 (%)				
Mean ± SD	30.88 ± 1.54	30.03 ± 2.56	30.29 ± 2.09	
95% CI	30.29–31.48	29.06–30.99	29.50–31.08	0.20
CV (%)	5.00	8.52	6.90	
Palmitoleic acid, 16:1n-7 (%)				
Mean ± SD	0.64 ± 0.21	0.54 ± 0.18	0.58 ± 0.22	
95% CI	0.56–0.72	0.47–0.61	0.50–0.67	0.39
CV (%)	32.36	33.93	38.29	
Stearic acid, 18:0 (%)				
Mean ± SD	16.75 ± 1.32	17.05 ± 1.44	16.24 ± 1.52	
95% CI	16.24–17.26	16.51–17.60	15.66–16.81	0.12
CV (%)	7.86	8.44	9.38	

Oleic acid, 18:1n-9 (%)				
Mean ± SD	8.03 ± 1.07	7.99 ± 1.51	7.92 ± 1.14	
95% CI	7.62 – 8.45	7.42 – 8.55	7.49 – 8.35	
CV (%)	13.30	18.86	14.35	0.96
Vaccenic acid, 18:1n-7 (%)				
Mean ± SD	2.40 ± 0.42	2.46 ± 0.57	2.37 ± 0.60	
95% CI	2.24 – 2.57	2.24 – 2.67	2.15 – 2.60	0.47
CV (%)	17.38	23.33	25.10	
Linoleic acid, 18:2n-6 (%)				
Mean ± SD	23.17 ± 2.78	23.62 ± 3.38	24.96 ± 3.48	
95% CI	22.10 – 24.24	22.35 – 24.90	23.65 – 26.28	0.15
CV (%)	12.01	14.29	13.96	
Dihomo-γ-linolenic acid, 20:3n-6 (%)				
Mean ± SD	3.00 ± 0.84	3.10 ± 1.07	2.83 ± 0.87	
95% CI	2.67 – 3.32	2.69 – 3.50	2.50 – 3.16	0.64
CV (%)	28.12	34.64	30.65	
Arachidonic acid, 20:4n-6 (%)				
Mean ± SD	10.52 ± 1.99	11.19 ± 2.32	10.81 ± 1.77	
95% CI	9.75 – 11.29	10.32 – 12.07	10.14 – 11.48	0.74
CV (%)	18.95	20.70	16.40	
Eicosapentaenoic acid, 20:5n-3 (%)				
Mean ± SD	0.44 ± 0.26	0.32 ± 0.16	0.35 ± 0.23	
95% CI	0.34 – 0.54	0.26 – 0.38	0.26 – 0.44	0.10
CV (%)	59.36	49.31	65.67	
Adrenic acid, 22:4n-6 (%)				
Mean ± SD	0.41 ± 0.13	0.46 ± 0.17	0.45 ± 0.18	
95% CI	0.36 – 0.46	0.39 – 0.52	0.38 – 0.52	0.59
CV (%)	31.63	36.95	40.81	
Docosapentaenoic acid, 22:5n-3 (%)				
Mean ± SD	0.63 ± 0.23	0.57 ± 0.13	0.51 ± 0.16	
95% CI	0.54 – 0.71	0.52 – 0.62	0.45 – 0.57	0.22
CV (%)	36.91	22.30	31.65	
Docosahexaenoic acid, 22:6n-3 (%)				
Mean ± SD	3.12 ± 0.86	2.76 ± 0.86	2.68 ± 0.92	
95% CI	2.79 – 3.45	2.43 – 3.08	2.33 – 3.03	0.11
CV (%)	27.59	31.32	34.28	
Ratio Arachidonic/Eicosapentaenoic acid				
Mean ± SD	30.35 ± 18.06	41.46 ± 17.38	45.25 ± 29.89	
95% CI	23.41 – 37.29	34.90 – 48.02	33.98 – 56.53	0.04
CV (%)	59.50	41.92	66.04	
Ratio Arachidonic/Docosahexaenoic acid				
Mean ± SD	3.57 ± 0.93	4.40 ± 1.43	4.48 ± 1.61	
95% CI	3.21 – 3.92	3.85 – 4.94	3.87 – 5.09	0.08
CV (%)	25.99	32.64	36.06	
Ratio n-6/n-3 polyunsaturated fatty acids				
Mean ± SD	9.57±2.84	11.29±3.42	11.97±3.61	
95% CI	8.42– 10.71	9.94 – 12.64	10.54 – 13.39	0.04
CV (%)	29.28	30.28	30.16	
Total saturated fatty acids (%)				
Mean ± SD	47.63 ± 2.08	47.08 ± 2.90	46.53 ± 3.01	
95% CI	46.83 – 48.43	45.99 – 48.18	45.39 – 47.66	0.17
CV (%)	4.37	6.17	6.47	
Total monounsaturated fatty acids (%)				
Mean ± SD	11.08 ± 1.16	10.98 ± 1.34	10.87 ± 1.45	
95% CI	10.63 – 11.52	10.47 – 11.49	10.33 – 11.42	0.98
CV (%)	10.51	12.21	13.33	
Total polyunsaturated fatty acids (%)				
Mean ± SD	41.29 ± 2.17	42.02 ± 3.04	42.60 ± 3.11	
95% CI	40.46 – 42.12	40.87 – 43.16	41.43 – 43.77	0.14
CV (%)	5.25	7.23	7.29	
Total n-3 polyunsaturated fatty acids (%)				
Mean ± SD	4.19 ± 1.16	3.65 ± 0.95	3.54 ± 1.06	
95% CI	3.74 – 4.63	3.29 – 4.00	3.14 – 3.94	0.08
CV (%)	27.69	26.16	29.89	
Total n-6 polyunsaturated fatty acids (%)				
Mean ± SD	37.10 ± 2.25	38.37 ± 2.63	39.06 ± 3.10	

95% CI	36.24 – 37.97	37.38 – 39.37	37.89 – 40.23	0.02
CV (%)	6.07	6.87	7.94	
<b>Desaturase activity</b>				
Delta-5 desaturase activity				
Mean ± SD	3.88 ± 1.58	4.05 ± 1.60	4.20 ± 1.53	
95% CI	3.27 – 4.48	3.44 – 4.65	3.62 – 4.78	0.75
CV (%)	40.70	39.51	36.39	
Delta-6 desaturase activity				
Mean ± SD	0.13 ± 0.05	0.14 ± 0.06	0.12 ± 0.05	
95% CI	0.12 – 0.15	0.11 – 0.16	0.10 – 0.14	0.35
CV (%)	34.48	42.51	40.01	

Values are mean ± standard deviation (SD), 95% confidence interval (CI) and coefficient of variation (CV). Between groups differences were estimated by the non-parametric test of Kruskal-Wallis. All the *p*-values are indicated.

**Table S4.** Overall changes in the levels of the main biomarkers examined in this study in the placebo (PLB) and chokeberry (AMj and AMj<sub>d</sub>) intervention groups.

Mean ± SD	78.51 ± 26.61	76.14 ± 25.69	-2.36 ± 34.66	0.69	91.54 ± 27.11	73.35 ± 20.96	-18.19±19.98	0.01	97.74 ±27.04	107.70 ± 64.23	9.96 ± 55.56	0.80	0.48
95% CI	63.45 – 93.56	61.61– 90.68	-21.97 –17.25		76.20 –106.88	61.49 – 85.21	-29.50 – -6.89		80.98 –114.50	67.89 –147.51	-24.48 –44.40		
CV (%)	33.90	33.73			29.61	28.58			27.67	59.63			

Values are mean ± standard deviation (SD), 95% confidence interval (CI) and coefficient of variation (CV). Change (Δ) is post-baseline. Intragroup differences (IG) were estimated by the non-parametric Wilcoxon test and between groups (BG) differences were estimated by the non-parametric Kruskal-Wallis test. All the *p*-values are indicated. LDL: low-density lipoprotein; oxLDL: oxidized low-density lipoprotein.

**Table S5.** Changes in the waist circumference and HDL-cholesterol values of women and men in the three intervention subgroups: placebo (PLB) and chokeberry juices (AMJ and AMJd).

	PLB				AMJ				AMJd				BG <i>p</i> -value		
	Baseline	End of treatment	Δ	IG <i>p</i> -value	Baseline	End of treatment	Δ	IG <i>p</i> -value	Baseline	End of treatment	Δ	IG <i>p</i> -value			
<b>Women</b>	PLB (n=14)				AMJ (n=17)				AMJd (n=21)						
<b>Waist circumference (cm)</b>															
Mean ± SD	89.57 ± 16.63	88.86 ± 16.06	-0.71 ± 4.76	0.09	90.18 ± 13.55	89.35 ± 13.21	-0.82 ± 2.79	0.28	86.38 ± 10.21	85.38 ± 10.05	-1.00 ± 2.32	0.07	0.72		
95% CI	80.86 – 98.28	80.45 – 97.27	-3.21 – 1.78		83.73 – 96.62	83.07 – 95.63	-2.15 – 0.50		82.01 – 90.75	81.08 – 89.68	-1.99 – -0.01				
CV (%)	18.56	18.07			15.03	14.78			11.82	11.77					
<b>HDL cholesterol (mmol/L)</b>															
Mean ± SD	1.86 ± 0.41	1.77 ± 0.44	-0.09 ± 0.24	0.21	1.71 ± 0.54	1.69 ± 0.51	-0.01 ± 0.17	0.42	1.78 ± 0.42	1.65 ± 0.45	-0.13 ± 0.22	0.02	0.57		
95% CI	1.64 – 2.07	1.54 – 2.00	-0.21 – 0.04		1.45 – 1.96	1.45 – 1.94	-0.09 – 0.07		1.60 – 1.96	1.46 – 1.85	-0.22 – -0.03				
CV (%)	22.10	24.75			31.66	30.41			23.87	27.45					
<b>Total cholesterol/HDL</b>															
Mean ± SD	3.14 ± 0.71	3.20 ± 0.70	0.06 ± 0.36	0.64	3.19 ± 0.90	3.15 ± 1.01	-0.04 ± 0.38	0.59	3.02 ± 0.78	3.21 ± 0.98	0.20 ± 0.53	0.11	0.86		
95% CI	2.77 – 3.51	2.83 – 3.57	-0.12 – 0.25		2.76 – 3.62	2.68 – 3.63	-0.22 – 0.14		2.68 – 3.35	2.79 – 3.63	-0.03 – 0.42				
CV (%)	22.65	21.87			28.21	31.91			25.86	30.52					
<b>LDL/HDL</b>															
Mean ± SD	2.13 ± 0.64	2.18 ± 0.66	0.05 ± 0.32	0.55	2.11 ± 0.78	2.11 ± 0.89	0.001 ± 0.36	0.87	2.01 ± 0.70	2.13 ± 0.87	0.12 ± 0.39	0.16	0.79		
95% CI	1.80–2.47	1.84–2.53	-0.12–0.22		1.74 – 2.47	1.68 – 2.53	-0.17 – 0.17		1.71 – 2.31	1.76 – 2.50	-0.04 – 0.29				
CV (%)	30.08	30.09			36.89	42.08			34.91	40.81					
<b>Men</b>	PLB (n=15)				AMJ (n=10)				AMJd (n=7)						
<b>Waist circumference (cm)</b>															
Mean ± SD	100.00 ± 8.47	98.71 ± 9.40	-1.29 ± 1.98	0.04	100.80 ± 12.44	99.00 ± 11.66	-1.80 ± 2.86	0.08	105.43 ± 7.21	103.86 ± 8.88	-1.57 ± 3.36	0.38	0.45		
95% CI	95.71 – 104.29	93.79 – 103.64	-2.32 – -0.25		93.45 – 108.15	92.11 – 105.89	-3.49 – -0.11		100.09 – 110.77	97.28 – 110.43	-4.06 – 0.92				
CV (%)	8.47	9.52			12.34	11.78			6.84	8.55					
<b>HDL cholesterol (mmol/L)</b>															
Mean ± SD	1.26 ± 0.23	1.18 ± 0.22	-0.08 ± 0.15	0.03	1.45 ± 0.43	1.39 ± 0.38	-0.07 ± 0.19	0.44	1.45 ± 0.34	1.36 ± 0.30	-0.09 ± 0.14	0.11	0.31		
95% CI	1.14 – 1.37	1.06 – 1.30	-0.15 – 0.0005		1.19 – 1.71	1.15 – 1.62	-0.19 – 0.06		1.20 – 1.71	1.13 – 1.58	-0.20 – 0.01				

CV (%)	18.17	19.01			29.43	27.53			23.70	22.43				
Total cholesterol/HDL														
Mean ± SD	4.29 ± 1.25	4.66 ± 1.14	0.33 ± 0.67	0.06	4.25 ± 1.68	4.53 ± 1.68	0.28 ± 1.09	0.72	3.60 ± 1.00	3.87 ± 0.82	0.26 ± 0.68	0.31	0.31	
95% CI	3.65 – 4.92	4.06 – 5.25	-0.02 – 0.68		3.21 – 5.29	3.49 – 5.58	-0.40 – 0.96		2.86 – 4.34	3.26 – 4.47	-0.24 – 0.77			
CV (%)	29.23	24.52			39.44	37.04			27.73	21.25				
LDL/HDL														
Mean ± SD	3.11 ± 1.16	3.30 ± 0.88	0.16 ± 0.64	0.27	3.05 ± 1.45	3.30 ± 1.29	0.25 ± 0.81	0.33	2.51 ± 0.88	2.73 ± 0.79	0.22 ± 0.57	0.31	0.38	
95% CI	2.52 – 3.70	2.84 – 3.76	-0.17 – 0.50		2.15 – 3.95	2.50 – 4.10	-0.25 – 0.75		1.85 – 3.16	2.14 – 3.32	-0.21 – 0.64			
CV (%)	37.41	26.79			47.49	39.10			35.21	29.14				

Values are mean ± standard deviations (SD), 95% confidence intervals (CI) and the coefficient of variation (CV). Change ( $\Delta$ ) is post-baseline. Intragroup (IG) differences were estimated by the non-parametric Wilcoxon test and between groups (BG) differences were estimated by the non-parametric Kruskal-Wallis test. All the  $p$ -values are indicated. LDL: low-density lipoprotein; HDL: high-density lipoprotein.

**Table S6.** Changes in the levels of plasma phospholipids fatty acids and desaturase activities in the placebo (PLB) and chokeberry (AMJ and AMJ<sub>d</sub>) intervention groups.

	PLB (n=26)				AMJ (n=27)				AMJ <sub>d</sub> (n=27)				BG $p$ -value
	Baseline	End of treatment	$\Delta$	IG $p$ -value	Baseline	End of treatment	$\Delta$	IG $p$ -value	Baseline	End of treatment	$\Delta$	IG $p$ -value	
Palmitic acid, 16:0 (%)													
Mean ± SD	30.88 ± 1.54	30.75 ± 1.19	-0.14 ± 2.18	0.77	30.03 ± 2.56	31.35 ± 1.25	1.32 ± 2.67	0.01	30.29 ± 2.09	31.36 ± 1.43	1.07 ± 2.15	0.005	0.10
95% CI	30.29 – 31.48	30.29 – 31.20	-0.97 – 0.70		29.06 – 30.99	30.87 – 31.82	0.31 – 2.33		29.50 – 31.08	30.82 – 31.90	0.26 – 1.88		
CV (%)	5.00	3.87			8.52	3.99			6.90	4.57			
Palmitoleic acid, 16:1n-7 (%)													
Mean ± SD	0.64 ± 0.21	0.54 ± 0.16	-0.10 ± 0.28	0.14	0.54 ± 0.18	0.52 ± 0.20	-0.02 ± 0.23	0.56	0.58 ± 0.22	0.54 ± 0.24	-0.05 ± 0.29	0.12	0.74
95% CI	0.56 – 0.72	0.48 – 0.60	-0.20 – 0.01		0.47 – 0.61	0.44 – 0.59	-0.11 – 0.06		0.50 – 0.67	0.45 – 0.63	-0.16 – 0.07		
CV (%)	32.36	30.59			33.93	39.31			38.29	43.88			
Stearic acid, 18:0 (%)													
Mean ± SD	16.75 ± 1.32	17.55 ± 1.56	0.80 ± 1.77	0.05	17.05 ± 1.44	17.83 ± 1.43	0.77 ± 1.38	0.002	16.24 ± 1.52	17.60 ± 1.47	1.36 ± 2.14	0.005	0.91
95% CI	16.24 – 17.26	16.94 – 18.15	0.12 – 1.47		16.51 – 17.60	17.29 – 18.37	0.25 – 1.30		15.66 – 16.81	17.05 – 18.16	0.56 – 2.17		
CV (%)	7.86	8.91			8.44	8.02			9.38	8.35			
Oleic acid, 18:1n-9 (%)													
Mean ± SD	8.03 ± 1.07	7.30 ± 1.72	-0.74 ± 1.82	0.02	7.99 ± 1.51	7.76 ± 1.37	-0.23 ± 1.99	0.65	7.92 ± 1.14	7.76 ± 1.60	-0.16 ± 1.53	0.08	0.25
95% CI	7.62 – 8.45	6.63 – 7.96	-1.44 – 0.04		7.42 – 8.55	7.24 – 8.27	-0.98 – 0.52		7.49 – 8.35	7.15 – 8.37	-0.73 – 0.42		
CV (%)	13.30	23.61			18.86	17.66			14.35	20.68			
Vaccenic acid, 18:1n-7 (%)													
Mean ± SD	2.40 ± 0.42	2.86 ± 0.61	0.46 ± 0.64	0.002	2.46 ± 0.57	2.71 ± 0.52	0.25 ± 0.83	0.18	2.37 ± 0.60	2.75 ± 0.71	0.38 ± 1.02	0.06	0.45
95% CI	2.24 – 2.57	2.63 – 3.10	0.21 – 0.70		2.24 – 2.67	2.51 – 2.91	-0.06 – 0.57		2.15 – 2.60	2.49 – 3.02	-0.003 – 0.77		
CV (%)	17.38	21.48			23.33	19.34			25.10	25.71			



Mean ± SD	11.08 ± 1.16	10.70 ± 1.74	-0.38 ± 2.12	0.29	10.98 ± 1.34	10.98 ± 1.46	0.001 ± 1.89	0.96	10.87 ± 1.45	11.05 ± 1.66	0.18 ± 1.84	0.85	0.69
95% CI	10.63 – 11.52	10.03 – 11.37	-1.19 – 0.43		10.47 – 11.49	10.43 – 11.53	-0.71 – 0.71		10.33 – 11.42	10.43 – 11.68	-0.51 – 0.87		
CV (%)	10.51	16.26			12.21	13.28			13.33	15.02			
Total polyunsaturated fatty acids (%)													
Mean ± SD	41.29 ± 2.17	40.99 ± 2.25	-0.30 ± 3.23	0.57	42.02 ± 3.04	39.85 ± 1.25	-2.17 ± 3.06	0.001	42.60 ± 3.11	39.96 ± 1.89	-2.64 ± 3.64	0.001	0.36
95% CI	40.46 – 42.12	40.13 – 41.86	-1.54 – 0.95		40.87 – 43.16	39.38 – 40.32	-3.32 – -1.01		41.43 – 43.77	39.25 – 40.68	-4.01 – -1.26		
CV (%)	5.25	5.49			7.23	3.13			7.29	4.74			
Total n-3 polyunsaturated fatty acids (%)													
Mean ± SD	4.19 ± 1.16	4.17 ± 1.21	-0.02 ± 0.74	0.87	3.65 ± 0.95	3.80 ± 1.28	0.16 ± 1.35	0.94	3.54 ± 1.06	3.81 ± 1.32	0.27 ± 1.37	0.25	0.29
95% CI	3.74 – 4.63	3.70 – 4.63	-0.30 – 0.26		3.29 – 4.00	3.32 – 4.28	-0.35 – 0.67		3.14 – 3.94	3.32 – 4.31	-0.25 – 0.79		
CV (%)	27.69	29.03			26.16	33.57			29.89	34.55			
Total n-6 polyunsaturated fatty acids (%)													
Mean ± SD	37.10 ± 2.25	36.83 ± 2.19	-0.28 ± 3.20	0.68	38.37 ± 2.63	36.05 ± 1.29	-2.33 ± 2.93	0.0005	39.06 ± 3.10	36.15 ± 1.89	-2.91 ± 3.37	0.0005	0.62
95% CI	36.24 – 37.97	35.98 – 37.67	-1.51 – 0.96		37.38 – 39.37	35.56 – 36.53	-3.43 – -1.22		37.89 – 40.23	35.44 – 36.86	-4.18 – -1.63		
CV (%)	6.07	5.96			6.87	3.57			7.94	5.23			
Delta-5 desaturase activity													
Mean ± SD	3.88 ± 1.58	4.26 ± 2.00	0.38 ± 1.84	0.71	4.05 ± 1.60	4.14 ± 1.26	0.10 ± 1.21	0.37	4.20 ± 1.53	4.19 ± 1.66	-0.01 ± 1.37	0.90	0.91
95% CI	3.27 – 4.48	3.49 – 5.03	-0.32 – 1.09		3.44 – 4.65	3.67 – 4.62	-0.36 – 0.55		3.62 – 4.78	3.56 – 4.82	-0.52 – 0.51		
CV (%)	40.70	46.92			39.51	30.50			36.39	39.70			
Delta-6 desaturase activity													
Mean ± SD	0.13 ± 0.05	0.12 ± 0.04	-0.01 ± 0.04	0.39	0.14 ± 0.06	0.12 ± 0.05	-0.01 ± 0.04	0.09	0.12 ± 0.05	0.12 ± 0.04	0.001 ± 0.04	0.98	0.95
95% CI	0.12 – 0.15	0.10 – 0.14	-0.03 – 0.003		0.11 – 0.16	0.10 – 0.14	-0.03 – 0.002		0.10 – 0.14	0.10 – 0.13	-0.01 – 0.02		
CV (%)	34.48	37.27			42.51	39.40			40.01	34.47			

Values are mean ± standard deviation (SD), 95% confidence interval (CI) and coefficient of variation (CV). Change (Δ) is post-baseline. Intragroup (IG) differences were estimated by the non-parametric Wilcoxon test and between groups (BG) differences were estimated by the non-parametric Kruskal-Wallis test. All the p-values are indicated.

**Table S7.** Habitual daily intake of total energy, main nutrients and fatty acids of the sample population included in the study and distributed into the placebo (PLB) and chokeberry (AMJ and AMJ<sub>d</sub>) intervention groups.

	PLB (n=29)	AMJ (n=27)	AMJ <sub>d</sub> (n=28)	p-value (between groups)
Energy (Kcal)				
Mean ± SD	2075.09 ± 597.27	2055.30 ± 499.27	2015.90 ± 555.04	
Median	2087.48	1901.62	1931.40	0.94
95% CI	1853.86 – 2296.32	1866.98 – 2243.63	1806.53 – 2225.26	
CV (%)	28.78	24.29	27.53	
Main macronutrients				
Fat (g)				
Mean ± SD	95.26 ± 33.01	89.25 ± 28.83	94.15 ± 33.84	
Median	97.30	81.21	86.57	0.81
95% CI	83.04 – 107.49	78.37 – 100.12	81.38 – 106.92	
CV (%)	34.65	32.30	35.95	
Protein (g)				
Mean ± SD	82.05 ± 25.24	80.81 ± 21.48	79.82 ± 24.81	
Median	86.65	76.96	75.31	0.86
95% CI	72.70 – 91.40	72.71 – 88.91	70.46 – 89.18	
CV (%)	30.77	26.58	31.08	
Carbohydrates (g)				
Mean ± SD	222.38 ± 77.41	226.75 ± 68.25	212.31 ± 61.89	
Median	219.12	202.82	204.76	0.82
95% CI	193.71 – 251.05	201.01 – 252.49	188.97 – 235.66	
CV (%)	34.81	30.10	29.15	
Main types of fatty acids				
Saturated fatty acids (g)				
Mean ± SD	28.54 ± 11.17	30.22 ± 12.08	31.50 ± 13.73	
Median	29.45	27.52	28.78	0.82
95% CI	24.40 – 32.68	25.66 – 34.77	26.32 – 36.68	
CV (%)	39.14	39.98	43.58	
Monounsaturated fatty acids (g)				
Mean ± SD	30.13 ± 11.66	28.27 ± 10.44	29.28 ± 12.93	
Median	28.03	25.37	25.71	0.84
95% CI	25.81 – 34.45	24.33 – 32.21	24.40 – 34.15	
CV (%)	38.70	36.92	44.15	
Polyunsaturated fatty acids (g)				
Mean ± SD	26.86 ± 13.67	22.29 ± 8.88	23.86 ± 8.63	
Median	24.23	20.05	23.83	0.60
95% CI	21.80 – 31.93	18.94 – 25.64	20.60 – 27.12	
CV (%)	50.89	39.82	36.19	

Values are mean ± standard deviation (SD), median, 95% confidence interval (CI) and coefficient of variation (CV). Between groups differences were estimated by the non-parametric test of Kruskal-Wallis. All the p-values are indicated.